Quoin Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.06 22:05
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -6.71, missing the estimate of USD -6.36.

EBIT: As of FY2025 Q3, the actual value is USD -4.082 M.

Financial Highlights

Cash Position

  • Quoin Pharmaceuticals had approximately $5.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The company expects that this, along with the $16.6 million upfront funding from a private placement closed in October 2025 and $3.3 million from warrant exercises, will support operations into 2027.

Net Loss

  • For the three months ended September 30, 2025, Quoin reported a net loss of approximately $3.9 million, compared to a net loss of approximately $2.3 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was approximately $11.5 million, compared to $6.7 million for the same period in 2024. The increase in net loss was primarily due to higher research and development expenditures.

Operating Expenses

  • Total operating expenses for the three months ended September 30, 2025, were $4,019,925, compared to $2,528,002 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $11,770,281, compared to $7,123,404 for the same period in 2024.

Other Income

  • Total other income for the three months ended September 30, 2025, was - $71,760, compared to - $178,117 for the same period in 2024. For the nine months ended September 30, 2025, other income was - $313,999, compared to - $472,206 for the same period in 2024.

Outlook / Guidance

  • Quoin Pharmaceuticals plans to use the proceeds from the private placement financing for general corporate purposes, including operating expenses, research and development, and advancing clinical development of QRX003 for Netherton Syndrome. The company expects to commence enrollment for both QRX003 pivotal studies for Netherton Syndrome in Q4 2025. The NETHERTON NOW awareness campaign continues to amplify the voices of patients, families, caregivers, and advocates for Netherton Syndrome.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.